Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder

P. V. Magalhães, O. M. Dean, A. I. Bush, D. L. Copolov, D. Weisinger, G. S. Malhi, K. Kohlmann, S. Jeavons, I. Schapkaitz, M. Anderson-Hunt, M. Berk

Research output: Contribution to journalReview ArticleResearchpeer-review

18 Citations (Scopus)

Abstract

Objectives: Bipolar disorder (BD) is intricately associated with chronic clinical conditions. Medical comorbidity is not only more prevalent in mood disorders, but is associated with increased costs, cognitive impairment and, ultimately, premature mortality. Oxidative stress and inflammation may mediate part of this association. To further investigate the association between medical comorbidity status and clinical improvement with adjuvant N acetyl cysteine (NAC) in the context of a placebo-controlled trial. Methods: Placebo-controlled randomized clinical trial assessing the effect of NAC over 24. weeks. Symptomatic and functional outcomes were collected over the study period. Medical comorbidities were self-reported, and we took special interest in cardiovascular and endocrine conditions. We evaluated change from baseline to endpoint and the interaction between change and reported medical comorbidities. Results: Fifty-one percent of patients reported have a cardiovascular or endocrine comorbidity. Although not found for depressive symptoms or quality of life, a significant interaction between medical comorbidity and change scores was consistently found for all functional outcomes. This indicated an advantage of NAC over placebo in those with a clinical comorbidity. Conclusion: Systemic illness moderated only the effect of NAC on functioning, not on depression. Demonstrating an improvement in functional outcomes with an agent that modulates redox and inflammatory pathways, this study lends empirical support to the idea that medical and psychiatric comorbidity are additive in contributing to allostatic states. One intriguing possibility is that comorbid clinical illness could be a marker for more severe oxidative stress states - and thus guide antioxidant use - in BD.

Original languageEnglish
Pages (from-to)132-135
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume37
Issue number1
DOIs
Publication statusPublished - 27 Apr 2012

Keywords

  • Bipolar disorder
  • Clinical trial
  • N acetyl cysteine
  • Oxidative stress
  • Systemic illness

Cite this

Magalhães, P. V. ; Dean, O. M. ; Bush, A. I. ; Copolov, D. L. ; Weisinger, D. ; Malhi, G. S. ; Kohlmann, K. ; Jeavons, S. ; Schapkaitz, I. ; Anderson-Hunt, M. ; Berk, M. / Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 ; Vol. 37, No. 1. pp. 132-135.
@article{883cbaea16214343871bbd8467e73146,
title = "Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder",
abstract = "Objectives: Bipolar disorder (BD) is intricately associated with chronic clinical conditions. Medical comorbidity is not only more prevalent in mood disorders, but is associated with increased costs, cognitive impairment and, ultimately, premature mortality. Oxidative stress and inflammation may mediate part of this association. To further investigate the association between medical comorbidity status and clinical improvement with adjuvant N acetyl cysteine (NAC) in the context of a placebo-controlled trial. Methods: Placebo-controlled randomized clinical trial assessing the effect of NAC over 24. weeks. Symptomatic and functional outcomes were collected over the study period. Medical comorbidities were self-reported, and we took special interest in cardiovascular and endocrine conditions. We evaluated change from baseline to endpoint and the interaction between change and reported medical comorbidities. Results: Fifty-one percent of patients reported have a cardiovascular or endocrine comorbidity. Although not found for depressive symptoms or quality of life, a significant interaction between medical comorbidity and change scores was consistently found for all functional outcomes. This indicated an advantage of NAC over placebo in those with a clinical comorbidity. Conclusion: Systemic illness moderated only the effect of NAC on functioning, not on depression. Demonstrating an improvement in functional outcomes with an agent that modulates redox and inflammatory pathways, this study lends empirical support to the idea that medical and psychiatric comorbidity are additive in contributing to allostatic states. One intriguing possibility is that comorbid clinical illness could be a marker for more severe oxidative stress states - and thus guide antioxidant use - in BD.",
keywords = "Bipolar disorder, Clinical trial, N acetyl cysteine, Oxidative stress, Systemic illness",
author = "Magalh{\~a}es, {P. V.} and Dean, {O. M.} and Bush, {A. I.} and Copolov, {D. L.} and D. Weisinger and Malhi, {G. S.} and K. Kohlmann and S. Jeavons and I. Schapkaitz and M. Anderson-Hunt and M. Berk",
year = "2012",
month = "4",
day = "27",
doi = "10.1016/j.pnpbp.2011.11.011",
language = "English",
volume = "37",
pages = "132--135",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier",
number = "1",

}

Magalhães, PV, Dean, OM, Bush, AI, Copolov, DL, Weisinger, D, Malhi, GS, Kohlmann, K, Jeavons, S, Schapkaitz, I, Anderson-Hunt, M & Berk, M 2012, 'Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 37, no. 1, pp. 132-135. https://doi.org/10.1016/j.pnpbp.2011.11.011

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. / Magalhães, P. V.; Dean, O. M.; Bush, A. I.; Copolov, D. L.; Weisinger, D.; Malhi, G. S.; Kohlmann, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Berk, M.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 37, No. 1, 27.04.2012, p. 132-135.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder

AU - Magalhães, P. V.

AU - Dean, O. M.

AU - Bush, A. I.

AU - Copolov, D. L.

AU - Weisinger, D.

AU - Malhi, G. S.

AU - Kohlmann, K.

AU - Jeavons, S.

AU - Schapkaitz, I.

AU - Anderson-Hunt, M.

AU - Berk, M.

PY - 2012/4/27

Y1 - 2012/4/27

N2 - Objectives: Bipolar disorder (BD) is intricately associated with chronic clinical conditions. Medical comorbidity is not only more prevalent in mood disorders, but is associated with increased costs, cognitive impairment and, ultimately, premature mortality. Oxidative stress and inflammation may mediate part of this association. To further investigate the association between medical comorbidity status and clinical improvement with adjuvant N acetyl cysteine (NAC) in the context of a placebo-controlled trial. Methods: Placebo-controlled randomized clinical trial assessing the effect of NAC over 24. weeks. Symptomatic and functional outcomes were collected over the study period. Medical comorbidities were self-reported, and we took special interest in cardiovascular and endocrine conditions. We evaluated change from baseline to endpoint and the interaction between change and reported medical comorbidities. Results: Fifty-one percent of patients reported have a cardiovascular or endocrine comorbidity. Although not found for depressive symptoms or quality of life, a significant interaction between medical comorbidity and change scores was consistently found for all functional outcomes. This indicated an advantage of NAC over placebo in those with a clinical comorbidity. Conclusion: Systemic illness moderated only the effect of NAC on functioning, not on depression. Demonstrating an improvement in functional outcomes with an agent that modulates redox and inflammatory pathways, this study lends empirical support to the idea that medical and psychiatric comorbidity are additive in contributing to allostatic states. One intriguing possibility is that comorbid clinical illness could be a marker for more severe oxidative stress states - and thus guide antioxidant use - in BD.

AB - Objectives: Bipolar disorder (BD) is intricately associated with chronic clinical conditions. Medical comorbidity is not only more prevalent in mood disorders, but is associated with increased costs, cognitive impairment and, ultimately, premature mortality. Oxidative stress and inflammation may mediate part of this association. To further investigate the association between medical comorbidity status and clinical improvement with adjuvant N acetyl cysteine (NAC) in the context of a placebo-controlled trial. Methods: Placebo-controlled randomized clinical trial assessing the effect of NAC over 24. weeks. Symptomatic and functional outcomes were collected over the study period. Medical comorbidities were self-reported, and we took special interest in cardiovascular and endocrine conditions. We evaluated change from baseline to endpoint and the interaction between change and reported medical comorbidities. Results: Fifty-one percent of patients reported have a cardiovascular or endocrine comorbidity. Although not found for depressive symptoms or quality of life, a significant interaction between medical comorbidity and change scores was consistently found for all functional outcomes. This indicated an advantage of NAC over placebo in those with a clinical comorbidity. Conclusion: Systemic illness moderated only the effect of NAC on functioning, not on depression. Demonstrating an improvement in functional outcomes with an agent that modulates redox and inflammatory pathways, this study lends empirical support to the idea that medical and psychiatric comorbidity are additive in contributing to allostatic states. One intriguing possibility is that comorbid clinical illness could be a marker for more severe oxidative stress states - and thus guide antioxidant use - in BD.

KW - Bipolar disorder

KW - Clinical trial

KW - N acetyl cysteine

KW - Oxidative stress

KW - Systemic illness

UR - http://www.scopus.com/inward/record.url?scp=84857794206&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2011.11.011

DO - 10.1016/j.pnpbp.2011.11.011

M3 - Review Article

VL - 37

SP - 132

EP - 135

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -